FOI – Trials for Cladribine/Mavenclad
Published 5 January 2026
© Crown copyright 2026
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/vmd-foieir-requests-september-2025/foi-trials-for-cladribinemavenclad
ATI1114 Request
Is there a trial ongoing or planned, to use Cladribine/Mavenclad, a chemotherapy medication, for dogs with Canine Degenerative Myelopathy (CDM)?
Our reply
We do not have a record of an Animal Test Certificate relating to Cladribine/ Mavenclad for use in dogs with Canine Degenerative Myelopathy and the VMD is not aware of any planned trials.